Skip to content
Contact Us

Investing in Tomorrow's Breakthrough Therapies

Dare Bioventures is committed to advancing innovative drug candidates that address significant gaps in current medical treatments. Our focus is on funding and supporting biotech innovations that target areas with high unmet medical need, accelerating the path from discovery to clinical impact.

Contact Us
Biotech researchers collaborating on drug development

Our Mission & Approach

While advancing transformative therapies that enhance public health, we deliver attractive, downside-protected returns you can count on. We partner with visionary scientists and entrepreneurs, providing capital, strategic guidance, and industry expertise to accelerate breakthrough treatments from concept to clinic. Our rigorous investment process and deep sector knowledge empower us to identify and nurture transformative biotech companies committed to improving patient outcomes and redefining the future of medicine.

Women_In_Bio_2 (2)

Managing Partner

Monica Berrondo, PhD

PhD in Chemical Engineering from Johns Hopkins University. Built and led YC-backed Macromoltek as founder & CEO. Active Nucleate mentor and reviewer for NIH, NSF & JHU.

Frank

General Partner

Frank Martin, PhD

PhD in Pharmacology from Columbia University and Novartis Post-Doc. Deployed over $100 M at Breakthrough T1D, supporting high-profile billion-dollar acquisitions.

Contact Dare Bioventures

Have questions about our investment approach or want to discuss your biotech innovation? Reach out to our team to explore partnership opportunities or learn more about how we support breakthrough drug candidates addressing high unmet medical needs.